This edition highlights:
- Belgian-Dutch Argenx’s deal for California’s Unnatural Products, worth up to $1.15 billion, as European biotechs buy US discovery platforms.
- EU governments’ backing for a one-year delay to methane rules on energy imports, a reprieve for US LNG exporters.
- Microsoft’s decision not to expand its Texas AI deal with UK-based Nscale ahead of Nscale’s New York IPO.
- The US Army’s pick of Czech group CSG’s US arm to bid on a $4.2 billion ammunition-plant program.
